## UNH: UnitedHealth Group Incorporated - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.26 indicates fundamental undervaluation. Quality metrics strong (ROE 18%).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($316.80)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. UnitedHealth (UNH) stock slips after hours as UnitedHealthcare delays remote monitoring policy**
- Source: ts2.tech | 20251229T180100 | Somewhat-Bearish | Relevance: 100%
- UnitedHealth Group Incorporated (UNH) shares fell after hours due to its UnitedHealthcare unit delaying a policy that would have tightened reimbursement for remote physiologic monitoring. This delay comes as investors anticipate UnitedHealth's full-year results and 2026 guidance, focusing on how the insurer plans to manage medical costs and regulatory risks. The market is also closely watching other industry developments, including scrutiny of insurer-owned pharmacy operations and a federal judge blocking Idaho's enforcement of unfair-competition law against UnitedHealthcare.

**2. 2026 People to Watch: Stephen Hemsley, UnitedHealth Group Inc.**
- Source: The Business Journals | 20251230T190840 | Somewhat-Bearish | Relevance: 100%
- Stephen Hemsley has returned to lead UnitedHealth Group after its stock plummeted and it missed earnings expectations. He faces the challenge of steering the healthcare giant through federal investigations and rising costs in 2026. Hemsley previously served as CEO from 2006 to 2017.

**3. UNH vs. ELV: Which Managed Care Stock Has the Edge Today?**
- Source: TradingView â€” Track All Markets | 20251230T170923 | Neutral | Relevance: 100%
- UnitedHealth Group (UNH) and Elevance Health, Inc. (ELV) are major players in the U.S. managed healthcare sector, both facing challenges from rising medical costs and regulatory scrutiny. While UNH boasts significant scale and its diversified Optum segment, it is dealing with margin pressures and regulatory investigations. ELV, however, appears to be in a stronger near-term position due to strategic market exits, the growth of its Carelon platform, and a more attractive valuation for investors.

**4. Segment Wealth Management LLC Sells 18,316 Shares of UnitedHealth Group Incorporated $UNH**
- Source: MarketBeat | 20251230T130842 | Neutral | Relevance: 100%
- Segment Wealth Management LLC significantly reduced its stake in UnitedHealth Group (NYSE:UNH) by 54.8% in Q3, selling 18,316 shares and ending the quarter with 15,102 shares valued at approximately $5.215 million. The article details UnitedHealth's solid Q3 earnings, revenue growth, and dividend payouts, alongside a mixed analyst sentiment with an average target price of $385.54. Institutional ownership of the company stands at 87.86%, as other firms also adjusted their positions.

**5. Fort Washington Investment Advisors Inc. OH Has $160.58 Million Stock Position in UnitedHealth Group Incorporated $UNH**
- Source: MarketBeat | 20251230T121055 | Somewhat-Bullish | Relevance: 100%
- Fort Washington Investment Advisors Inc. OH has increased its stake in UnitedHealth Group Incorporated (UNH) by 1.6%, now holding 465,048 shares valued at $160.58 million. This position represents approximately 0.9% of Fort Washington's portfolio. Institutional investors collectively own about 87.9% of UnitedHealth Group, which recently reported strong earnings, 12.2% revenue growth, and a quarterly dividend.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 15 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (-0.3%)
- Blackrock Inc.: 8.2% (-1.4%)
- State Street Corpora: 4.9% (-1.8%)
- JPMORGAN CHASE & CO: 4.1% (+85.6%)
- Geode Capital Manage: 2.4% (+2.2%)

### Key Risks

1. Long-term trend broken: trading 5.1% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_20 improving +2.8% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.26 suggests fair value with growth premium. Forward P/E 18.7x stretched relative to 9% growth. Balance sheet: $5.1B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $300.9B |
| Beta | 0.43 |
| 52W Range | $234.60 - $606.36 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.26 |
| Forward P/E | 18.7 |
| Current P/E | 20.3 |
| YoY Growth | 8.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -2.4% to 0.4% (+2.8% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.6pp (needs >4.0% for momentum thesis). MRS_5 at 1.4% confirms short-term momentum alignment. Below SMA200 (0.95x), long-term trend not supportive. RSI neutral at 52. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.42% (CS: 54) | Neutral |
| RSI_14 | 51.8 | Neutral |
| MACD Histogram | 0.22 | Bullish |
| vs SMA20 | 1.004x | Above |
| vs SMA50 | 0.995x | Below |
| vs SMA200 | 0.949x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $332.22
- **Stop Loss:** $316.80 (4.6% risk)
- **Target:** $363.06 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 85
- **Position Value:** $28,238.70
- **Portfolio %:** 28.24%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-01-15 (Est: $2.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.81 | $2.92 | +4.0% |
| 2025Q2 | $4.45 | $4.08 | -8.2% |
| 2025Q1 | $7.29 | $7.20 | -1.3% |
| 2024Q4 | $6.74 | $6.81 | +1.1% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*